Form 4: XBiotech Director Tevi Troy Granted 56,000 Stock Options

XBiotech Inc. Director Tevi Troy received a grant of 56,000 nonstatutory stock options with an exercise price of $2.64, vesting in two tranches.

Summary

• Tevi David Troy, a Director of XBiotech Inc. (XBIT), was granted 56,000 nonstatutory stock options.
• The grant date for these options was October 1, 2025.
• The exercise price for the options is $2.64 per share, which was the closing sales price on the Nasdaq Stock Market on the grant date.
• The options vest in two equal portions: the first at four months from the grant date (February 1, 2026) and the second at ten months from the grant date (August 1, 2026).
• The options have an expiration date of ten years from the grant date, specifically October 1, 2035.
• Following this transaction, Tevi Troy beneficially owns 56,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued director involvement and provides an incentive for future company performance, aligning director interests with shareholders. There are no immediate negative financial implications, only potential future dilution upon exercise.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the company's stock price increases above the exercise price.
• This is a standard form of compensation for directors, indicating continued engagement and incentive for long-term performance.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholder equity, though this is a common aspect of equity compensation plans.

Risks

• The value of the options is contingent on XBiotech's common stock price exceeding the $2.64 exercise price; if the stock price remains below this, the options may expire worthless.
• Future market conditions or company performance could negatively impact the stock price, reducing the potential benefit of these options.

Future Outlook

The grant of these stock options suggests an expectation of future growth and increased shareholder value, as the options are designed to incentivize the director to contribute to the company's long-term success and stock price appreciation.

Management Comments

• The reporting person was granted nonstatutory stock options under the Company's 2025 Equity Incentive Plan.
• The options vest in two equal portions at four months and ten months from the Grant Date with an expiry of ten years from the Grant Date.

Industry Context

Equity compensation, such as stock option grants, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key personnel, including directors, by linking their compensation to the company's performance and long-term shareholder value creation. This aligns with typical compensation structures seen across the sector.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice, comparable to similar arrangements at other small to mid-cap biotech companies like Agenus Inc. or Sorrento Therapeutics, where equity incentives are used to align management and director interests with long-term company performance.
• The vesting schedule (two tranches over ten months) is a common approach to encourage continued service and performance, similar to vesting schedules observed in director compensation packages at companies such as BioNTech or Moderna, albeit often with different scales of grants depending on company size and stage.

Corporate Governance

Related Party Transactions

• The grant of stock options to Tevi David Troy, a Director of XBiotech Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased director alignment and incentive for stock price appreciation.
• Director (Tevi Troy): Receives a significant equity incentive, aligning personal financial interests with the company's long-term performance.

Next Steps

• The options will vest in two equal portions on February 1, 2026, and August 1, 2026, at which point the director will be able to exercise them.

Key Dates

Keywords

XBiotech, XBIT, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Beneficial Ownership